title: Structural basis for retinoic X receptor repression on the tetramer.
abstract: Retinoic X receptor (RXR) is a master nuclear receptor in the processes of cell development and homeostasis. Unliganded RXR exists in an autorepressed tetramer, and agonists can induce RXR dimerization and coactivator recruitment for activation. However, the molecular mechanisms involving the corepressor recruitment and antagonist-mediated repression of RXR are still elusive. Here we report the crystal structure of RXRα ligand-binding domain (LBD) complexed with silencing mediator for retinoid and thyroid hormone receptors (SMRT) corepressor motif. As the first structural report on the unliganded nuclear receptor bound to the corepressor motif, RXRαLBD-SMRT exhibits a significant structural rearrangement, compared with apoRXRαLBD tetramer. To elucidate further the molecular determinants for RXR repression by its antagonist, we also determine the crystal structure of RXRαLBD-SMRT complexed with the identified antagonist rhein. In the structure, two rhein molecules and two SMRT peptides are in the RXRαLBD tetramer, different from the case in RXRαLBD-SMRT structure, where four SMRT peptides bind to RXRαLBD tetramer. It seems that rhein induces a displacement of SMRT motif by activation function 2 (AF-2) motif binding to the receptor. Combining our current work with the published results, structural superposition of RXRαLBDs in different states reveals that RXR uses an overlapped binding site for coactivator, corepressor, and AF-2 motifs, whereas the AF-2 motif adopts different conformations for agonist or antagonist interaction and coactivator or corepressor recruitment. Taken together, we thus propose a molecular model of RXR repression on the tetramer.
authors: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
authors: Haitao
authors: H
authors: Zhang
authors: Lili
authors: L
authors: Chen
authors: Jing
authors: J
authors: Chen
authors: Hualiang
authors: H
authors: Jiang
authors: Xu
authors: X
authors: Shen
references: J Mol Biol. 2011 Mar 18;407(1):13-20
references: 21262235
references: Cell. 2010 Sep 3;142(5):822-822.e1
references: 20813267
references: Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):5842-7
references: 11972046
references: Mol Endocrinol. 1997 Apr;11(4):470-80
references: 9092799
references: Methods Enzymol. 1997;276:307-26
references: 27754618
references: Mol Cell Biol. 2001 Mar;21(5):1747-58
references: 11238912
references: Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3412-7
references: 21300871
references: J Ethnopharmacol. 2009 Jan 21;121(2):313-7
references: 19061946
references: J Biol Chem. 2006 Dec 8;281(49):37773-81
references: 16990259
references: Pharmacol Rev. 2006 Dec;58(4):760-72
references: 17132853
references: Cancer. 2003 Nov 15;98(10):2207-13
references: 14601091
references: Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
references: 15572765
references: Cell Mol Life Sci. 2000 Nov;57(12):1748-69
references: 11130180
references: J Biol Chem. 1998 Nov 13;273(46):30175-82
references: 9804773
references: Oncogene. 2007 Aug 13;26(37):5439-49
references: 17694085
references: Planta Med. 2010 Jan;76(1):27-33
references: 19639539
references: Genes Dev. 2000 Sep 1;14(17):2229-41
references: 10970886
references: Nature. 2002 Feb 14;415(6873):813-7
references: 11845213
references: Cell Cycle. 2007 Jul 15;6(14):1748-52
references: 17630505
references: J Biol Chem. 2011 Jan 21;286(3):1868-75
references: 21084305
references: Exp Clin Endocrinol Diabetes. 2007 Oct;115(9):571-6
references: 17943690
references: Mol Cell Biol. 1999 Sep;19(9):6448-57
references: 10454590
references: EMBO J. 2000 Jun 1;19(11):2592-601
references: 10835357